7606 Federal Register / Vol. 75, No. 34 / Monday, February 22, 2010 / Notices 

FDA’s burden estimate is based on 

prior experience with Internet panel 

experiments similar to the study 

proposed here. Sixty panel members 

will take part in a pre-test of the study, 

estimated to last 30 minutes (0.5 hours), 

for a total of 30 hours. Approximately 

15,000 respondents will complete a 

screener to determine eligibility for 

participation in the study, estimated to 

take 1 minute (0.016 hours), for a total 

of 125 hours. Fifty-four hundred (5,400) 

respondents will complete the full 

study, estimated to last 30 minutes (0.5 

hours), for a total of 2,700 hours. The 

total estimated burden is 2,970 hours. 

Dated: February 16, 2010. 

Leslie Kux, 

Acting Assistant Commissioner for Policy. 

[FR Doc. 2010–3320 Filed 2–19–10; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Advisory Committee to the Director 

(ACD), Centers for Disease Control and 

Prevention (CDC): Notice of Charter 

Renewal 

This gives notice under the Federal 

Advisory Committee Act (Pub. L. 92– 

463) of October 6, 1972, that the 

Advisory Committee to the Director, 

Centers for Disease Control and 

Prevention of the Department of Health 

and Human Services, has been renewed 

for a 2-year period extending through 

February 1, 2012. 

Contact Person for More Information: 

Anne C. Haddix, PhD, Designated 

Federal Officer, ACD, CDC, 1600 Clifton 

Road, NE., M/S D14, Atlanta, Georgia 

30333. Telephone 404–639–0663. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both the 

Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Dated: February 11, 2010. 

Andre Tyler, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2010–3148 Filed 2–19–10; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control 

Special Emphasis Panel (SEP): 

Healthy Passages Longitudinal Study of 

Youth, Funding Opportunity 

Announcement (FOA) DP 10–007, 

Initial Review. 

In accordance with Section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the aforementioned meeting: 

Time and Date: 1 p.m.–3 p.m., April 20, 

2010 (Closed). 

Place: Teleconference. 

Status: The meeting will be closed to the 

public in accordance with provisions set 

forth in Section 552b(c)(4) and (6), Title 5 

U.S.C., and the Determination of the Director, 

Management Analysis and Services Office, 

CDC, pursuant to Public Law 92–463. 

Matters To Be Discussed: The meeting will 

include the initial review, discussion, and 

evaluation of applications received in 

response to ‘‘Healthy Passages Longitudinal 

Study of Youth, FOA DP 10–007.’’ 

Contact Person for More Information: 

Michael Dalmat, DRPH., Scientific Review 

Officer, National Center for Chronic Disease 

and Health Promotion, Office of the Director, 

Extramural Research Program Office, 4770 

Buford Highway, NE., Mailstop K–92, 

Atlanta, GA 30341, Telephone: (770) 488– 

6423, E-mail: MED1@cdc.gov. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both CDC and the Agency for Toxic 

Substances and Disease Registry. 

Dated: February 10, 2010. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2010–3146 Filed 2–19–10; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–1996–N–0006] (formerly 

Docket No. 1996N–0277) 

Safety and Efficacy Review for 

Additional Ingredients in Over-theCounter Drug Products for Human 

Use; Request for Environmental 

Impact Data and Information 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Request for data and 

information. 

SUMMARY: We (Food and Drug 

Administration (FDA)) are requesting 

data and information regarding the 

potential environmental impact of 

amending over-the-counter (OTC) drug 

monographs to include certain active 

ingredients not previously marketed in 

the United States or marketed in the 

United States under approved 

applications after the OTC drug review 

began in 1972. Thirteen active 

ingredients have been found eligible for 

potential inclusion in OTC drug 

monographs based on time and extent 

applications (TEAs). We are currently 

evaluating the safety and effectiveness 

of these ingredients. 

DATES: Submit data, information, and 

general comments by May 24, 2010. 

ADDRESSES: Submit electronic or written 

data, information, and general 

comments in response to this document. 

Submit electronic comments to http:// 

regulations.gov. Submit written 

comments to the Division of Dockets 

Management HFA–305), 5630 Fishers 

Lane, rm. 1061, Rockville, MD 20852. 

FOR FURTHER INFORMATION CONTACT: 

Michael L. Koenig, Center for Drug 

Evaluation and Research, Food and 

Drug Administration, 10903 New 

Hampshire Ave., Bldg. 22, rm. 5411, 

Silver Spring, MD 20993–0002, 301– 

796–2090. 

SUPPLEMENTARY INFORMATION: 

I. Ingredients Affected by This Notice 

We are currently evaluating the safety 

and effectiveness of 13 active 

ingredients found eligible for possible 

addition to an OTC drug monograph via 

the TEA process described in 21 CFR 

330.14. The ingredients under review 

are shown in table 1 of this document: 


cprice-sewell on DSK2BSOYB1PROD with NOTICES